Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by NImmune Biopharma
NImmune Biopharma Acquires Development and Commercialization Rights to Omilancor in Asian Markets
October 23, 2024
From
NImmune Biopharma
Via
Business Wire
NImmune Biopharma to Participate in UBS Virtual Biotechnology Private Company Symposium
September 16, 2024
From
NImmune Biopharma
Via
Business Wire
NImmune Biopharma Announces R&D Collaboration with BioTherapeutics, Inc. to Advance the Next Wave of Inflammation and Immunology Precision Medicines
September 05, 2024
From
NImmune Biopharma
Via
Business Wire
NImmune Biopharma Presents Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus at the American College of Rheumatology Convergence 2023 (#ACR23)
November 14, 2023
From
NImmune Biopharma
Via
Business Wire
NImmune Biopharma Announces Positive Results of Omilancor in Ulcerative Colitis and Crohn’s disease at the American College of Gastroenterology 2023 Annual Scientific Meeting
October 23, 2023
From
NImmune Biopharma
Via
Business Wire
NImmune Biopharma Provides Update on Omilancor Clinical Development Programs in Ulcerative Colitis and Crohn’s Disease
May 17, 2023
From
NImmune Biopharma
Via
Business Wire
NImmune Biopharma Announces Precision Medicine Research Collaboration with NIMML Institute to Advance the Clinical Development of its LANCL Immunoregulatory Therapeutic Pipeline
May 03, 2023
From
NImmune Biopharma
Via
Business Wire
Josep Bassaganya-Riera Launches NImmune Biopharma with Phase 3-Ready Clinical Candidate Omilancor for the Treatment of Ulcerative Colitis and Crohn’s Disease
March 22, 2023
From
NImmune Biopharma
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.